How is the dosage of melphalan determined? Dosage of melphalan

Dosage] Oral: daily, divided doses, a total of 4 7 days, this product and prednisone in combination, may be more effective than single use, the combination of drugs is usually carried out intermittently, and the treatment of effective patients will not change the efficacy of extending the course of treatment for more than one year. If there is no significant bone marrow toxicity, repeat the dose within 4 to 6 weeks.

Multiple myeloma: the combination of this drug and prednisone is more effective than the use of this drug alone. Typical dosing is mg kilogram days, given in divided doses for 4 days, repeated after 6 weeks.

Ovarian adenocarcinoma: Typically** the plan is to take mg kilogram a day for a period of 5 days. Repeat every 4 to 8 weeks or immediately after bone marrow recovery.

This drug has also been injected intravenously for ovarian cancer. Malignant melanoma: Local perfusion of this drug has been used as an adjunct to surgery for early-stage malignant melanoma** and as a palliative treatment for advanced but locally localized disease**.

Soft tissue sarcoma: Local perfusion of this drug has been used for all stages of soft tissue sarcoma, usually with surgery. Polycythemia vera:

The dose of remission induction is 6-10 mg per day for 5-7 days, and then 2-4 mg per day until satisfactory disease control is achieved. The maintenance ** dose is 2-6 mg per week. Blood changes should be carefully monitored during maintenance**, and the dose should be adjusted frequently based on blood counts.

Dosage for Renal Disorders: For patients with moderate to severe renal disorders, the initial dose of intravenous therapy should be reduced by 50 per penny, and subsequent doses should be determined according to blood reactions.

Remember.

Usage and Dosage】 1Multiple myeloma: oral.

Daily, divided doses, a total of 4 days, 6 weeks after repeating the course of treatment, this product and prednisone in combination, may be more effective than single use, the combination of drugs is usually indirect, to ** effective people to extend the course of treatment for more than one year will not improve the efficacy, intravenous infusion: under the condition of peripheral blood count recovery, can be repeated after an appropriate interval (such as 1 time every 4 weeks), the high-dose regimen intravenous dose is generally 100 200mg m2 (, but when the dose exceeds 140mg m2, it should be supplemented with autologous bone marrow transplantation. 2.

Advanced ovarian cancer: oral. Daily for a total of 5 days, when peripheral blood is restored or the course of treatment is repeated every 4 to 8 weeks.

Intravenous administration: 1 mg kg (40 mg m2) for single drug application, usually repeated after 4 weeks, and intravenous registered dose for combination with other cytotoxic agents), 4 to 6 weeks apart. 3.

Breast cancer: oral. Daily or 6 mg m2 for 5 days, repeated every 6 weeks, with a dose reduced when bone marrow toxicity is observed.

4.Polycythemia vera: induction of remission.

Take 6 to 10 mg daily for 5 to 7 days, then 2 to 4 mg daily until symptoms are satisfactorily controlled. 5.Pediatric advanced neuroblastoma:

100 240 mg m2, repeated every 4-6 weeks.

Because melphalan has a myelosuppressive effect, it is necessary to monitor the blood picture (blood count) frequently during the ** period, and if necessary, suspend the drug or adjust the dose. or as directed by a doctor. Based on the pharmacokinetic data currently established, a reduction in the dose of oral melphalan in patients with moderate to severe renal insufficiency is not absolutely recommended, but the initial dose should be reduced cautiously without tremor.

Reference usage and dosage] oral: daily, divided into dry mountain pants to take, a total of 4 7 days, this product and prednisone combination, may be more effective than single use, the combination of drugs is usually carried out intermittently, the most effective person to extend the course of treatment for more than one year will not change the efficacy. If there is no significant bone marrow toxicity, repeat the dose within 4 to 6 weeks.

Multiple myeloma:

The typical dosage is milligrams per kilogram of body weight per day, divided into four days, and repeated after six weeks. Extending the course of treatment for more than one year in patients with ** will not change the efficacy. Melphalan may be more effective in combination with prednisone than alone.

Ovarian adenocarcinoma: the typical ** regimen is milligrams per kilogram of body weight per day for five days, repeated every 4 8 weeks or when peripheral blood is restored; The dose should be reduced when bone marrow toxicity occurs.

Advanced Breast Cancer:

Oral melphalan at milligrams per kilogram of body weight or 6 milligrams per square meter of body surface area per day for 5 days, repeated every six weeks, or intravenous melphalan for closed cases**.

True erythrocytic polybulbar syndrome:

During the induction of remission phase, 6 10 mg per day for 5 7 days, followed by 2 4 mg per day until symptoms are satisfactorily controlled, and the maintenance dose can be 2 6 mg once a week, during which the patient must be carefully and carefully controlled hematically, and the dose adjusted appropriately based on the results of blood counts.

Patients with renal insufficiency:

Based on the pharmacokinetic data currently established, a reduction in the dose of oral melphalan in patients with moderate to severe renal insufficiency is not absolutely recommended, but the initial dose should be reduced cautiously.